- Home
- BAX vs ARWR Comparison
BAX vs ARWR Comparison
Compare BAX & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAX | ARWR |
|---|---|---|
| Founded | 1931 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 10.2B |
| IPO Year | 1994 | 2009 |
Fundamental Metrics
Financial Performance| Metric | BAX | ARWR |
|---|---|---|
| Price | $19.43 | $73.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $21.00 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 5.9M | 1.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.24% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,244,000,000.00 | $16,142,321.00 |
| Revenue This Year | $1.96 | N/A |
| Revenue Next Year | $2.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.72 | N/A |
| 52 Week Low | $15.73 | $14.30 |
| 52 Week High | $32.04 | $82.26 |
Technical Indicators
Market Signals| Indicator | BAX | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 59.93 | 46.21 |
| Support Level | $18.95 | $70.49 |
| Resistance Level | $19.90 | $77.39 |
| Average True Range (ATR) | 0.62 | 3.63 |
| MACD | 0.04 | -0.89 |
| Stochastic Oscillator | 76.60 | 26.81 |
Price Performance
Historical ComparisonAbout BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.